PARSOL® Shield: Is the U.S. sunscreen market ready for a scientific breakthrough?
For the first time in over 20 years, the U.S. sunscreen market may be on the verge of a regulatory and scientific shift. PARSOL® Shield (Bemotrizinol), a globally established UV filter, is currently under FDA review, offering formulators an opportunity to elevate their products to top international standards.
Already in use around the world, PARSOL® Shield is known for its outstanding photostability, broad-spectrum efficacy (UVA + UVB), and strong safety profile, supported by more than two decades of global market use. Unlike legacy U.S. filters such as Avobenzone or Oxybenzone, PARSOL® Shield resists photodegradation and is highly compatible with modern formulation systems, enabling more stable, elegant, and high-performing sunscreen products.
With an FDA decision expected by March 2026, leading brands are already reconsidering launch timelines and planning ahead for potential reformulations. Incorporating PARSOL® Shield could bring a competitive edge, combining scientific robustness with consumer-demanded performance.
At Eurofins C&PC, we support this transition through a full suite of services: SPF efficacy testing, photostability analysis, formulation support, and international regulatory consulting. Whether you're exploring initial prototypes or preparing for post-approval market entry, we help turn innovation into compliant, high-performing products.